^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
OmniSeq INSIGHT

Company:
LabCorp
Type:
Other Approval
Related tests:

Details

Evidence
OmniSeq INSIGHT is a comprehensive, tissue-based, next generation sequencing genomic profiling device clinically and analytically validated for all solid tumors. The test is designed to detect genomic variants, signatures, and immune gene expression to provide physicians with clinically actionable evidence to inform therapeutic treatment decisions and identify potential clinical trial options based on an individual genomic profile of each patient. Results are intended for use by qualified health care professionals in accordance with professional guidelines in oncology for management of patients with solid neoplasms, and is not conclusive or prescriptive for labeled use of any specific therapeutic product.
Cancer:
Solid Tumor
Gene:
HRD (Homologous Recombination Deficiency), MSI (Microsatellite instability), PD-L1 (Programmed death ligand 1), TMB (Tumor Mutational Burden)
Method:
Next generation sequencing (NGS)